Becton Dickinson and Company (NYSE:BDX): Closing price $82.70
Becton Dickinson’s segment BD Medical said that the FDA has approved the BD PhaSeal Closed System Transfer Device under the newly created ONB code. The BD PhaSeal System is the first and sole approved CSTD under the new code, which was created for devices having specific indications for use with antineoplastic and other hazardous drugs. The FDA clearance was based on three criteria: no transfer of environmental contaminants, no escape of hazardous drug or vapor concentration, and prevention of microbial ingress. Shares closed up 0.49 percent on the day at $82.70, and have been traded in a 52-week range of $71.56 to $82.31.